2Hapani S,Chu D,Wu ShenHong.Risk of gastrointestinal perforation in patients with cancer treated with bevacizumab:a meta-analysis[J].Lancet Oncol,2009,10(6):559-568.
3Kabbinavar F F,Flynn P J,Kozloff M,et al.Gastrointestinal perforation associated with bevacizumab use in metastatic colorectal cancer:results from a large treatment observational cohort study[J].Eur J Cancer,2012,48(8):1126-1132.
5Badgwell B D,Camp E R,Feig B,et al.Management of bevacizumab-associated bowel perforation:a case series and review of the literature[J].Ann Oncol,2008,19(3):577-582.
2Hurwitz H, Fehrenbacher L, Novotny W, et al. Bevacizumab plusirinotecan,fluorouracil and leucovorin for metastatic colorectalcancer[J]. N Engl J Med, 2004, 350(23) : 2335-2342.
3Kabbinavar FF,Schulz J, McCleod M, et al. Addition of bevaci-zumab to bolus fluorouracil and leucovorin in first-line metastaticcolorectal cancer: results of a randomized phase II trial[ J]. J ClinOncol, 2005,23(16) : 3697-36705.
4Hurwitz HI,Fehrenbacher L,Hainsworth JD,et al. Bevacizumab incombination with fluorouracil and leucovorin : an active regimen forfirst-line metastatic colorectal cancer[ J]. J Clin Oncol, 2005,23(15): 3502-3508.
5Burger RA,Brady MF,Bookman MA,et al. Risk factors for GI ad-verse events in a phase M randomized trial of bevacizumab in first-line therapy of advanced ovarian cancer : A Gynecologic OncologyGroup Study[J]. J Clin Oncol, 2014, 32( 12) : 1210-1217.
6Kabbinavar FF, Flynn PJ,Kozloff M,et al. Gastrointestinal perfora-tion associated with bevacizumab use in metastatic colorectal canc-er :results from a large treatment observational cohort study [ J ].Eur J Cancer, 2012,48(8) : 1126-1132.
7Spigel DR,Townley PM,Waterhouse DM,et al. Randomized phaseII study of bevacizumab in combination with chemotherapy in pre-viously untreated extensive-stage small-cell lung cancer: resultsfrom the SALUTE trial[J]. J Clin Oncol, 2011,29(16) : 2215-2222.
8White D, Kassim A, Bhaskar B, et al. Results from AMBER, arandomized phase 2 study of bevacizumab and bortezomib versusbortezomib in relapsed or refractory multiple myeloma[ J]. Canc-er, 2013,119(2) : 339-347.
9Kindler HL,Karrison TG,Gandara DR,et al. Multicenter,double-blind ,placebo-controlled, randomized phase II trial of gemcit-abine/cisplatin plus bevacizumab or placebo in patients with ma-lignant mesothelioma [ J ]. J Clin Oncol,2012, 30 (20) : 2509-2515.
10Kim KB, Sosman JA, Fruehauf JP, et al. BEAM: a randomizedphase II study evaluating the activity of bevacizumab in combina-tion with carboplatin plus paclitaxel in patients with previously un-treated advanced melanoma[ J]. J Clin Oncol, 2012, 30( 1 ) : 34-41.
